BSE List Price : ₹

NSE List Price : ₹

subscription

Category	Times
QIBs	0.06x
HNIs	1.05x
Retail	0.05x
Total : 0.42x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	1	38	₹14,896
Retail Maximum	13	494	₹193,648
S-HNI Minimum	14	532	₹208,544
S-HNI Maximum	67	2,546	₹998,032
B-HNI Minimum	68	2,584	₹1,012,928

About the Company

Sai Parenteral’s Ltd., established in 2001, is a prominent pharmaceutical company engaged in the research, development, and manufacturing of pharmaceutical products. The company operates across two key segments: the production and sale of its own branded formulations, as well as contract manufacturing for international pharmaceutical companies.

Its product portfolio covers a broad spectrum of therapeutic categories, including cardiovascular, neuropsychiatric, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology.

The company offers its products in multiple dosage forms such as tablets, injections, and syrups. Sai Parenteral’s serves a diverse customer base comprising government institutions, pharmaceutical companies, public and private hospitals, and large distributors across India. It operates five manufacturing units in India, primarily based in Hyderabad, and is recognized for producing medicines that meet international quality standards and certifications.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2023	₹97.03	₹89.78	₹4.38	₹133.96
2024	₹155.18	₹142.63	₹8.42	₹268.10
2025	₹163.74	₹143.84	₹14.43	₹272.39
Sep 2025	₹89.43	₹78.27	₹7.76	₹376.24

Company Promoter

Anil Kumar Karusala

Vijitha Gorrepati

Karusala Aruna

Know before investing

• • Strengths

  Broad formulations portfolio with a proven track record: The company is present across various therapeutic categories and dosage forms, which helps minimize reliance on any single product segment.

  Significant emphasis on CDMO operations: Its CDMO capabilities enable access to long-term agreements, improved margins, and collaborations with global clients.

• • Risks

  Concentration of manufacturing facilities in specific regions: The company’s units are largely based in Telangana and Andhra Pradesh, making it vulnerable to regional disruptions or changes in local regulations.

  Risk related to regulatory compliance: The manufacturing units are subject to regular inspections and audits, and any unfavorable findings could affect operations, reputation, and financial performance.

Objects of the Issue & Utilisation of proceeds

Capacity expansion and upgradation of manufacturing facilities.
Establishment of a new R&D Centre;.
Repayment / prepayment of certain outstanding borrowings.
Working capital requirements.
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and.
General corporate purposes.

Company  Address

Sai Parenteral’s Ltd.
Plot No 39
5th floor, Lavanya Arcade, Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/

IPO Registrar

Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html

IPO Review

Avoid